LifeStance Health Group (NASDAQ:LFST) Given New $7.00 Price Target at Barclays

LifeStance Health Group (NASDAQ:LFST) had its price objective lifted by Barclays from $6.00 to $7.00 in a report published on Monday morning,Benzinga reports. The brokerage currently has an underweight rating on the stock.

Separately, UBS Group dropped their price target on shares of LifeStance Health Group from $9.00 to $7.50 and set a “neutral” rating on the stock in a research note on Thursday, August 15th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $8.42.

LifeStance Health Group Stock Up 0.4 %

Shares of LFST opened at $7.39 on Monday. The company’s 50-day simple moving average is $6.94 and its 200-day simple moving average is $6.22. The stock has a market capitalization of $2.83 billion, a PE ratio of -28.42 and a beta of 1.24. LifeStance Health Group has a 1 year low of $4.64 and a 1 year high of $9.20. The company has a debt-to-equity ratio of 0.20, a quick ratio of 1.22 and a current ratio of 1.22.

LifeStance Health Group (NASDAQ:LFST) last issued its earnings results on Thursday, November 7th. The company reported ($0.02) earnings per share for the quarter, beating the consensus estimate of ($0.07) by $0.05. The firm had revenue of $312.70 million for the quarter, compared to analysts’ expectations of $302.25 million. LifeStance Health Group had a negative net margin of 7.90% and a negative return on equity of 6.67%. The firm’s revenue was up 18.9% compared to the same quarter last year. During the same quarter last year, the company earned ($0.17) earnings per share. Analysts forecast that LifeStance Health Group will post -0.22 earnings per share for the current fiscal year.

Insider Buying and Selling at LifeStance Health Group

In other LifeStance Health Group news, insider Ann Varanakis sold 5,269 shares of LifeStance Health Group stock in a transaction dated Friday, August 23rd. The stock was sold at an average price of $6.28, for a total value of $33,089.32. Following the completion of the sale, the insider now owns 263,007 shares in the company, valued at $1,651,683.96. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 6.60% of the stock is owned by company insiders.

Institutional Trading of LifeStance Health Group

A number of institutional investors have recently modified their holdings of LFST. CIBC Asset Management Inc acquired a new position in LifeStance Health Group during the 2nd quarter worth approximately $53,000. Bessemer Group Inc. raised its position in shares of LifeStance Health Group by 43.4% in the 1st quarter. Bessemer Group Inc. now owns 9,143 shares of the company’s stock valued at $56,000 after purchasing an additional 2,768 shares in the last quarter. Algert Global LLC acquired a new position in shares of LifeStance Health Group in the 2nd quarter valued at approximately $57,000. Victory Capital Management Inc. raised its position in shares of LifeStance Health Group by 27.0% in the 2nd quarter. Victory Capital Management Inc. now owns 14,407 shares of the company’s stock valued at $71,000 after purchasing an additional 3,063 shares in the last quarter. Finally, Park Edge Advisors LLC acquired a new position in shares of LifeStance Health Group in the 3rd quarter valued at approximately $73,000. Hedge funds and other institutional investors own 85.50% of the company’s stock.

About LifeStance Health Group

LifeStance Health Group, Inc, through its subsidiaries, provides outpatient mental health services to children, adolescents, adults, and geriatrics in the United States. The company offers patients a suite of mental health services, including psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy.